Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $19.2857.

Several equities research analysts have commented on CADL shares. Stifel Nicolaus assumed coverage on shares of Candel Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $22.00 price objective for the company. Cantor Fitzgerald began coverage on Candel Therapeutics in a research note on Monday, April 20th. They issued an “overweight” rating on the stock. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Candel Therapeutics in a research note on Thursday. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Finally, Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th.

More Candel Therapeutics News

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $23 price target, implying substantial potential upside from recent trading levels. The firm’s outlook reflects expectations for future earnings growth and progress in Candel’s pipeline. HC Wainwright reaffirms Buy rating and price target
• Positive Sentiment: Management highlighted “meaningful execution” toward a biologics license application (BLA) submission in the fourth quarter. Candel is targeting its first commercial product in 2027, making regulatory progress a key catalyst for the stock. CADL rises as biotech targets 2027 commercial launch
• Neutral Sentiment: Bank of America raised its price target from $9 to $12 but maintained a Neutral rating. The revised target is close to the recent share price, suggesting the analyst sees limited near-term upside despite the higher valuation estimate. Bank of America raises CADL price target
• Negative Sentiment: Candel reported a second-quarter loss of $0.52 per share, substantially worse than the $0.27 consensus estimate. The earnings miss highlights continued cash-burn and execution risk for the clinical-stage biotechnology company. Candel second-quarter earnings release
• Negative Sentiment: HC Wainwright modestly reduced its FY2028 and FY2029 EPS estimates to $0.69 and $1.41, respectively. Although the firm retained its Buy rating and $23 target, the estimate cuts indicate slightly lower expectations for Candel’s long-term profitability.

Insider Buying and Selling at Candel Therapeutics

In other news, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares of the company’s stock, valued at $778,261.72. This trade represents a 23.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.02, for a total value of $70,140.00. Following the sale, the chief technology officer owned 83,865 shares in the company, valued at $840,327.30. The trade was a 7.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Candel Therapeutics

Several institutional investors have recently added to or reduced their stakes in CADL. Janus Henderson Group PLC purchased a new stake in Candel Therapeutics during the first quarter worth about $845,000. Halter Ferguson Financial Inc. raised its position in Candel Therapeutics by 20.9% in the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after acquiring an additional 155,996 shares during the period. Renaissance Technologies LLC purchased a new position in Candel Therapeutics in the first quarter valued at about $63,000. Bank of New York Mellon Corp boosted its stake in Candel Therapeutics by 43.1% in the first quarter. Bank of New York Mellon Corp now owns 136,266 shares of the company’s stock valued at $668,000 after acquiring an additional 41,058 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Candel Therapeutics during the 2nd quarter valued at approximately $419,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Performance

NASDAQ CADL opened at $11.72 on Friday. The company has a fifty day moving average price of $9.68 and a 200-day moving average price of $7.40. The firm has a market cap of $858.72 million, a price-to-earnings ratio of -8.31 and a beta of -0.51. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $11.95.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). As a group, equities research analysts predict that Candel Therapeutics will post -0.91 EPS for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.